Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: Pharmacokinetics and pharmacodynamics

Diabetes Care

Volumn 36, Issue 1, 2013, Pages 41-48

  Shin, Andrea ^a   Camilleri, Michael ^a   Busciglio, Irene ^a   Burton, Duane ^a   Stoner, Elizabeth ^b   Noonan, Patrick ^b   Gottesdiener, Keith ^b   Smith, Steven A ^c   Vella, Adrian ^c   Zinsmeister, Alan R ^d  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Rhythm Pharmaceuticals   (United States)

^c MAYO CLINIC   (United States)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; PLACEBO; PROLACTIN; RM 131; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH EMPTYING; VITAL SIGN;

CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GHRELIN;

EID: 84872040988     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1128     Document Type: Article

References (39)

1. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009;136:1225-1233
2. Hyett B, Martinez FJ, Gill BM, et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 2009;137:445-452
3. Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med 2002;113:449-455 (Pubitemid 35335795)
4. Punkkinen J, Färkkilä M, Mätzke S, et al. Upper abdominal symptoms in patients with type 1 diabetes: unrelated to impairment in gastric emptying caused by autonomic neuropathy. Diabet Med 2008;25:570-577 (Pubitemid 351590890)
5. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012;107:82-88
6. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1999;22:503-507 (Pubitemid 29106912)
7. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007;356:820-829
8. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463-467 (Pubitemid 13005553)
9. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322:1028-1031 (Pubitemid 20146660)
10. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007;26:1251-1258 (Pubitemid 47620416)
11. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008;103:416-423 (Pubitemid 351248749)
12. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998;47:67-70 (Pubitemid 28065309)
13. O'Grady G, Du P, Lammers WJ, et al. High-resolution entrainment mapping of gastric pacing: a new analytical tool. Am J Physiol Gastrointest Liver Physiol 2010;298:G314-G321
14. McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010;8:947-954; quiz e116
15. Watkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet Med 2003;20:58-63 (Pubitemid 36098866)
16. Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009;6:343-352
17. Murray CD, Martin NM, Patterson M, et al.Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54:1693-1698 (Pubitemid 41697666)
18. Ang D, Nicolai H, Vos R, et al. Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil 2009;21:528-533, e8-e9
19. Cremonini F, Camilleri M, Vazquez Roque M, et al. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions. Gastroenterology 2006;131:1431-1439 (Pubitemid 44708949)
20. Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29:1179-1187
21. Camilleri M, Iturrino J, Bharucha AE, et al. Performance characteristics of scintigraphic-measurement of gastricemptying of solids in healthy participants. Neurogastroenterol Motil. 2 July 2012 [Epub ahead of print]
22. Brogna A, Loreno M, Catalano F, et al. Radioisotopic assessment of gastric emptying of solids in elderly subjects. Aging Clin Exp Res 2006;18:493-496 (Pubitemid 46351179)
23. Horowitz M, Maddern GJ, Chatterton BE, Collins PJ, Harding PE, Shearman DJ. Changes in gastric emptying rates with age. Clin Sci (Lond) 1984;67:213-218 (Pubitemid 14086652)
24. O'Donovan D, Hausken T, Lei Y, et al. Effect of aging on transpyloric flow, gastric emptying, and intragastric distribution in healthy humans - impact on glycemia. Dig Dis Sci 2005;50:671-676 (Pubitemid 40558459)
25. Kao CH, Lai TL, Wang SJ, Chen GH, Yeh SH. Influence of age on gastric emptying in healthy Chinese. Clin Nucl Med 1994;19:401-404 (Pubitemid 24142880)
26. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456-1462
27. Vazquez Roque MI, Camilleri M, Stephens DA, et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology 2006;131:1717-1724 (Pubitemid 44958529)
28. Revicki DA, Camilleri M, Kuo B, et al. Development and content validity of a gastroparesis cardinal symptomindex daily diary. Aliment Pharmacol Ther 2009;30:670-680
29. Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptomoutcomes in gastroparesis clinical trials: validity and responsiveness of the gastroparesis cardinal symptom index-daily diary (GCSI-DD). Neurogastroenterol Motil 2012;24:456-463, e215-e216
30. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil 2006;18:263-283
31. Wo JM, Ejskjaer N, Hellström PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data. Aliment Pharmacol Ther 2011;33:679-688
32. Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010;22:1069-e281
33. Fassino S, Daga GA, Mondelli V, et al. Hormonal and metabolic responses to acute ghrelin administration in patients with bulimia nervosa. Psychoneuroendocrinology 2005;30:534-540 (Pubitemid 40461787)
34. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-4911 (Pubitemid 32157685)
35. van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004;25:426-457 (Pubitemid 38780667)
36. Sharma D, Morrison G, Joseph F, Purewal TS, Weston PJ. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 2011;54:2768-2770
37. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 2011;9:567-576, e1-4
38. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2011;9:5-12; quiz e7
39. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007;13:3425-3429 (Pubitemid 47162015)